[CAS NO. 1269826-44-9] OSBPL7-IN-1
PRODUCTS SPECIFICATIONS [1269826-44-9]
DESCRIPTION [1269826-44-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 463.28 |
| Molecular Formula | C20H19Cl2F3N2O3 |
| SMILES | FC(F)(F)COC1=C(C2=CC(Cl)=C(C=C2)Cl)C=C(C=N1)C(N[C@H]3[C@@H](CCCC3)O)=O |
Summary
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression [1] .
In Vitro
OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female Balb/c mice induced by Adriamycin (ADR) [1] |
| Dosage: | 100 mg/kg |
| Administration: | Oral gavage; daily; for 28 days |
| Result: | Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 269.82 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1585 mL | 10.7926 mL | 21.5852 mL |
| 5 mM | 0.4317 mL | 2.1585 mL | 4.3170 mL |
| 10 mM | 0.2159 mL | 1.0793 mL | 2.1585 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.49 mM); Clear solution